Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of topical diclofenac to prevent fruquintinib-induced hand-foot syndrome
jRCTs031250630Phase 2Recruiting
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diclofenac and fruquintinib in Erythrodysesthesia syndrome (PPE). Primary endpoint: Incidence of Grade 2 or higher hand-foot syndrome within 2 months. Started May 2026; status: recruiting.
02
Drugs
diclofenacfruquintinib
03
Conditions
Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on jRCTs031250630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250630.